SEOUL, South Korea and SYRACUSE, N.Y. — September 2, 2025 — Leads & Copy — LOTTE BIOLOGICS (CEO James Park) announced a late-stage to commercial contract manufacturing partnership with a U.S.-based global biopharmaceutical company. The partnership covers a Phase 3 program advancing into new indications, extending to commercial supply after potential approvals. The term of the contract extends until middle of 2030.
LOTTE BIOLOGICS stated that the partnership reaffirms the company’s commercial scale manufacturing capabilities and quality leadership in the global market, while highlighting the geographical advantages of its U.S. manufacturing footprint.
This marks the third major partnership secured in 2025, underscoring LOTTE BIOLOGICS’ progress in line with the industry’s reshoring trend and supply chain realignment in the U.S. biomanufacturing sector. Leveraging its dual-site operations at Syracuse NY and Songdo, Korea, the company expands collaboration with U.S.-based firms and broadens its global client base.
A LOTTE BIOLOGICS representative said, “This late-stage to commercial partnership demonstrates strong client confidence in our global network and technical expertise. LOTTE is proud to support our partner’s indication expansion strategy and to help accelerate the availability of innovative therapies for patients worldwide.”
Contact:
(There was no contact information included in the release.)
